Exelixis Cash Flow Statement
NASDAQ: EXELHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Exelixis free cash flow
In fiscal 2025, Exelixis generated $884.3 million of operating cash flow and spent $8.4 million on capital expenditures. That left free cash flow of $875.8 million, a free-cash-flow margin of 37.7% of revenue. Free cash flow was up 30.4% from the prior year's $671.5 million.
Exelixis returned $947.5 million to shareholders through share repurchases, equal to 108% of free cash flow.
Summary generated from market data by MetaCap's automated system. Methodology
Exelixis cash flow statement (annual)
| Fiscal year (USD) | FY 20252026-01-02 | FY 20242025-01-03 | FY 20232023-12-29 | FY 20222022-12-30 | FY 20212021-12-31 | FY 20202021-01-01 | FY 20192020-01-03 | FY 20182018-12-28 | FY 20172017-12-29 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 782.57M | 521.27M | 207.76M | 182.28M | 231.06M | 111.78M | 321.01M | 690.07M | 154.23M | -70.22M |
| Net Income growth (YoY) | +50.13% | +150.89% | +13.98% | -21.11% | +106.71% | -65.18% | -53.48% | +347.44% | — | — |
| Depreciation & Amortization | 29.05M | 28.80M | 25.72M | 20.88M | 13.63M | 9.14M | 8.35M | 4.92M | 1.19M | 1.00M |
| Stock-Based Compensation | 112.98M | 93.84M | 106.34M | 107.57M | 119.82M | 105.07M | 56.60M | 40.63M | 23.94M | 22.91M |
| Change in Working Capital | -191.20M | -13.45M | -17.11M | -15.28M | -39.01M | -40.14M | 67.08M | -77.54M | -16.12M | 224.36M |
| Operating Cash Flow | 884.27M | 699.97M | 333.32M | 362.61M | 400.80M | 208.98M | 526.96M | 415.72M | 165.61M | 206.30M |
| Capital Expenditures | -8.43M | -28.43M | -40.47M | -27.71M | -54.23M | -30.34M | -12.83M | -33.30M | -21.14M | -1.70M |
| Investing Cash Flow | 350.44M | -116.78M | -26.95M | -524.41M | -42.88M | -131.22M | -587.25M | -297.85M | 36.80M | -216.05M |
| Share Repurchases | -947.51M | -652.03M | -550.38M | 0 | 0 | — | — | — | — | — |
| Debt Repaid | — | — | — | — | — | — | 0 | 0 | -185.79M | — |
| Financing Cash Flow | -969.59M | -628.81M | -546.05M | 586.00K | -14.80M | -25.13M | 12.55M | 9.69M | -169.93M | 19.80M |
| Net Change in Cash | 265.11M | -45.62M | -239.68M | -161.21M | 343.12M | 52.63M | -47.74M | 127.56M | 32.48M | 10.05M |
| Free Cash Flow | 875.84M | 671.54M | 292.86M | 334.91M | 346.58M | 178.64M | 514.12M | 382.42M | 144.47M | 204.59M |
This table shows 10 annual periods of Exelixis's cash flow statement, from FY 2025 back to FY 2016, across 13 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow EXEL's reporting calendar. What is a cash flow statement?